Phase 2 Parkinson's Disease Trial, Not Yet Recruiting NCT07738107 Sponsor: Atrium Therapeutics Condition: Parkinson's Disease
Back to Parkinsons Disease

Phase 2 Parkinson's Disease Trial, Not Yet Recruiting

NCT07738107
Not Yet Recruiting Phase 2

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Adults between 18 and 65 years of age.
  • People who have had genetic testing that found a change in the PRKAG2 gene, classified as disease-causing, likely disease-causing, or of uncertain significance.
  • People who have symptoms or signs consistent with a condition called PRKAG2 Syndrome.
  • People who are able and willing to follow all study procedures as required.
  • People who are able and willing to undergo a procedure where a small tissue sample is taken from the heart muscle (this applies to Part A of the study).

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who are pregnant or currently breastfeeding.
  • People who have significant problems with their liver, kidneys, blood, or heart that could increase the risks of taking part in the study.
  • People with very severe heart failure (classified as NYHA Class IV) or whose heart is pumping at less than 45% of its normal capacity.
  • People who have recently had a significant heart-related health event or procedure (confirm with trial site for specific timeframes).
  • People who have previously been treated with certain experimental therapies or a type of genetic medicine called oligonucleotide therapies within time periods defined by the study protocol.
  • People who have any other condition that, in the opinion of the study doctor, may affect their suitability to participate (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 4 August 2026

Contact this trial

Phone: 283-227-6543

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
Atrium Therapeutics
Registry
ClinicalTrials.gov
Start date
1 October 2026
Est. completion
1 May 2028

Primary endpoints

Incidence of treatment-emergent adverse events (TEAEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 4 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov